Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Turning Point Therapeutics, Inc. | EVP & Chief Financial Officer | Common Stock | 0 | $76.00 | Aug 17, 2022 | Direct | |
Turning Point Therapeutics, Inc. | EVP & Chief Financial Officer | Stock Option (right to buy) | 0 | Aug 17, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TPTX | Turning Point Therapeutics, Inc. | Aug 17, 2022 | 3 | -$2.26M | 4 | Aug 17, 2022 | EVP & Chief Financial Officer |
TPTX | Turning Point Therapeutics, Inc. | Jul 27, 2022 | 1 | -$88.7K | 4 | Jul 29, 2022 | EVP & Chief Financial Officer |
TPTX | Turning Point Therapeutics, Inc. | Feb 9, 2022 | 2 | $0 | 4 | Feb 11, 2022 | EVP & Chief Financial Officer |
TPTX | Turning Point Therapeutics, Inc. | Jul 26, 2021 | 2 | $0 | 4 | Jul 27, 2021 | EVP & Chief Financial Officer |
TPTX | Turning Point Therapeutics, Inc. | Jul 26, 2021 | 0 | $0 | 3 | Jul 27, 2021 | EVP & Chief Financial Officer |